Table 2.
Endpoint in aHUS (complement-mediated HUS) patients
| TMA event-free status, n | 28 |
| n (%) | 19 (67.9) |
| 95% CI | 47.6–84.1 |
| Complete TMA response, n | 18 |
| n (%) | 5 (27.8) |
| 95% CI | 9.7–53.5 |
| Hematologic outcome | |
| Hematologic normalization, n | 18 |
| n (%) | 7 (38.9) |
| 95% CI | 17.3–64.3 |
| Platelet count normalization, n | 23 |
| n (%) | 13 (56.5) |
| 95% CI | 34.5–76.8 |
| LDH normalization, n | 22 |
| n (%) | 12 (54.5) |
| 95% CI | 32.2–75.6 |
| Hemoglobin improvement ≥ 2 g/dl, n | 28 |
| n (%) | 14 (50.0) |
| 95% CI | 30.6–69.4 |
| Renal outcome | |
| Serum creatinine level decrease by ≥ 25%, n | 28 |
| n (%) | 16 (57.1) |
| 95% CI | 37.2–75.5 |
| eGFR improvement by ≥ 15 ml/min/1.73 m2, n | 26 |
| n (%) | 4 (15.4) |
| 95% CI | 4.4–34.9 |
CI confidence interval, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase, TMA thrombotic microangiopathy